NGNE earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -7.18. Updated 2026-07-23.
Neurogene (NGNE) Research Hub
Neurogene (NGNE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 23.54 USD (-0.04%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.18, market cap 0.57B. This hub links to the full technical, earnings and options research available for NGNE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.54 USD (-0.04%) |
| 52-week range | 21.04 USD – 43.66 USD |
| Trend regime | Range |
| 14-day RSI | 43.4 (Bearish) |
| Trailing P/E | -7.18 |
| Market cap | 0.57B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for NGNE
Covered Call on NGNE: how it works, illustrative setup around the real 23.54 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NGNE: how it works, illustrative setup around the real 23.54 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NGNE: how it works, illustrative setup around the real 23.54 USD price, max profit/loss, breakeven and when to use it. Educational.
NGNE technical analysis: range, last 23.54 USD, RSI 43.4, 52w range 21.04 USD–43.66 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is NGNE in?
Neurogene (NGNE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NGNE in an uptrend or downtrend?
As of 2026-10-26, NGNE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NGNE's trailing P/E ratio?
NGNE's trailing P/E is -7.18, with a market cap of 0.57B. See the earnings research page for full valuation detail.
When does NGNE next report earnings?
NGNE is next scheduled to report earnings on 2026-08-10.